Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Endovascular port-a-cath rescue in acute thrombotic superior vena cava syndrome.

Amberger H, Baumgartner I, Kucher N, Schindewolf M.

J Vasc Surg Cases Innov Tech. 2019 May 22;5(2):169-173. doi: 10.1016/j.jvscit.2019.03.005. eCollection 2019 Jun.

2.

Land use change in an agricultural landscape causing degradation of soil based ecosystem services.

Baude M, Meyer BC, Schindewolf M.

Sci Total Environ. 2019 Apr 1;659:1526-1536. doi: 10.1016/j.scitotenv.2018.12.455. Epub 2019 Jan 2.

PMID:
31096362
3.

Claudication Caused By Stenosis of Arteria Lusoria-Case Report and Review of Literature.

Tuleja A, Baumgartner I, Schindewolf M.

Clin Med Insights Case Rep. 2019 Apr 18;12:1179547619842187. doi: 10.1177/1179547619842187. eCollection 2019.

4.

Fondaparinux in heparin-induced thrombocytopenia: A decade's worth of clinical experience.

Schindewolf M.

Res Pract Thromb Haemost. 2018 Dec 4;3(1):9-11. doi: 10.1002/rth2.12169. eCollection 2019 Jan. No abstract available.

5.

Data on the impact of peripheral artery disease and of type 2 diabetes mellitus on the risk of cardiovascular events.

Saely CH, Schindewolf M, Zanolin D, Heinzle CF, Vonbank A, Silbernagel G, Leiherer A, Drexel H, Baumgartner I.

Data Brief. 2018 Nov 3;21:1716-1720. doi: 10.1016/j.dib.2018.10.153. eCollection 2018 Dec.

6.

Single and combined effects of peripheral artery disease and of type 2 diabetes mellitus on the risk of cardiovascular events: A prospective cohort study.

Saely CH, Schindewolf M, Zanolin D, Heinzle CF, Vonbank A, Silbernagel G, Leiherer A, Drexel H, Baumgartner I.

Atherosclerosis. 2018 Dec;279:32-37. doi: 10.1016/j.atherosclerosis.2018.09.031. Epub 2018 Oct 6.

PMID:
30399464
7.

Low incidence of heparin-induced skin lesions in orthopedic surgery patients with low-molecular-weight heparins.

Schindewolf M, Paulik M, Kroll H, Kaufmann R, Wolter M, Boehncke WH, Lindhoff-Last E, Recke A, Ludwig RJ.

Clin Exp Allergy. 2018 Aug;48(8):1016-1024. doi: 10.1111/cea.13159. Epub 2018 Jun 5.

PMID:
29683226
8.

Reply: Fondaparinux and Direct Oral Anticoagulants: Promising Anticoagulant for Management of Heparin-Induced Thrombocytopenia.

Schindewolf M, Banik N, Lindhoff-Last E.

J Am Coll Cardiol. 2018 Apr 17;71(15):1710-1712. doi: 10.1016/j.jacc.2018.02.026. No abstract available.

9.

Poor attainment of lipid targets in patients with symptomatic peripheral artery disease.

Dopheide JF, Papac L, Schindewolf M, Baumgartner I, Drexel H.

J Clin Lipidol. 2018 May - Jun;12(3):711-717. doi: 10.1016/j.jacl.2018.02.013. Epub 2018 Mar 1.

PMID:
29574071
10.

Efficacy Outcomes of Endovascular Versus Surgical Revascularization in Critical Limb Ischemia: Results From a Prospective Cohort Study.

Schindewolf M, Fuss T, Fink H, Gemperli A, Haine A, Baumgartner I.

Angiology. 2018 Sep;69(8):677-685. doi: 10.1177/0003319717750486. Epub 2018 Jan 21.

PMID:
29355026
11.

Haemostaseological complication management in caval and iliac venous stenting.

Kohler C, Fuss T, Schweizer R, Baumgartner I, Kucher N, Schindewolf M.

Vasa. 2018 Apr;47(3):243-246. doi: 10.1024/0301-1526/a000686. Epub 2018 Jan 16.

12.

Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia.

Schindewolf M, Steindl J, Beyer-Westendorf J, Schellong S, Dohmen PM, Brachmann J, Madlener K, Pötzsch B, Klamroth R, Hankowitz J, Banik N, Eberle S, Müller MM, Kropff S, Lindhoff-Last E.

J Am Coll Cardiol. 2017 Nov 28;70(21):2636-2648. doi: 10.1016/j.jacc.2017.09.1099.

13.

Nadroparin carries a potentially high risk of inducing cutaneous delayed-type hypersensitivity responses.

Schindewolf M, Recke A, Zillikens D, Lindhoff-Last E, Ludwig RJ.

Contact Dermatitis. 2017 Jul;77(1):35-41. doi: 10.1111/cod.12764. Epub 2017 Mar 14.

PMID:
28294347
14.

Blood RNA biomarkers in prodromal PARK4 and rapid eye movement sleep behavior disorder show role of complexin 1 loss for risk of Parkinson's disease.

Lahut S, Gispert S, Ömür Ö, Depboylu C, Seidel K, Domínguez-Bautista JA, Brehm N, Tireli H, Hackmann K, Pirkevi C, Leube B, Ries V, Reim K, Brose N, den Dunnen WF, Johnson M, Wolf Z, Schindewolf M, Schrempf W, Reetz K, Young P, Vadasz D, Frangakis AS, Schröck E, Steinmetz H, Jendrach M, Rüb U, Başak AN, Oertel W, Auburger G.

Dis Model Mech. 2017 May 1;10(5):619-631. doi: 10.1242/dmm.028035. Epub 2017 Jan 20.

15.

Feasibility of stereotactic MRI-based image guidance for the treatment of vascular malformations: a phantom study.

Schwalbe M, Haine A, Schindewolf M, von Tengg-Kobligk H, Williamson T, Weber S, Baumgartner I, Fuss T.

Int J Comput Assist Radiol Surg. 2016 Dec;11(12):2207-2215. Epub 2016 May 27.

PMID:
27234374
16.

The Role of Platelets in Venous Thromboembolism.

Montoro-García S, Schindewolf M, Stanford S, Larsen OH, Thiele T.

Semin Thromb Hemost. 2016 Apr;42(3):242-51. doi: 10.1055/s-0035-1570079. Epub 2016 Feb 29. Review.

PMID:
26926584
17.

Antifactor Xa Activity for the Management of Anticoagulation during Cardiac Surgery.

Reyher C, Würfel C, Lindhoff-Last E, Meybohm P, Zacharowski K, Moritz A, Schindewolf M, Weber CF.

Thorac Cardiovasc Surg. 2016 Sep;64(6):494-500. doi: 10.1055/s-0035-1570035. Epub 2016 Jan 12.

PMID:
26757210
18.

Thrombophilia and risk of VTE recurrence according to the age at the time of first VTE manifestation.

Weingarz L, Schindewolf M, Schwonberg J, Hecking C, Wolf Z, Erbe M, Lindhoff-Last E, Linnemann B.

Vasa. 2015 Jul;44(4):313-23. doi: 10.1024/0301-1526/a000447.

PMID:
26314364
19.

Tolerance of Fondaparinux in Immediate-type Hypersensitivity to Heparins.

Trog LM, Kahle B, Schindewolf M, Jappe U, Ludwig RJ.

Am J Med. 2015 Nov;128(11):e21-2. doi: 10.1016/j.amjmed.2015.06.024. Epub 2015 Jul 11. No abstract available.

PMID:
26169891
20.

Thrombosis of the inferior vena cava and malignant disease.

Kraft C, Schuettfort G, Weil Y, Tirneci V, Kasper A, Haberichter B, Schwonberg J, Schindewolf M, Lindhoff-Last E, Linnemann B.

Thromb Res. 2014 Sep;134(3):668-73. doi: 10.1016/j.thromres.2014.07.012. Epub 2014 Jul 18.

PMID:
25081831
21.

Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT)--findings from the GerHIT multi-centre registry study.

Schindewolf M, Steindl J, Beyer-Westendorf J, Schellong S, Dohmen PM, Brachmann J, Madlener K, Pötzsch B, Klamroth R, Hankowitz J, Banik N, Eberle S, Kropff S, Müller MM, Lindhoff-Last E.

Thromb Res. 2014 Jul;134(1):29-35. doi: 10.1016/j.thromres.2014.03.029. Epub 2014 Mar 18.

PMID:
24703295
22.

Prevalence of established risk factors for venous thromboembolism according to age.

Linnemann B, Weingarz L, Schindewolf M, Schwonberg J, Weber A, Herrmann E, Lindhoff-Last E.

J Vasc Surg Venous Lymphat Disord. 2014 Apr;2(2):131-9. doi: 10.1016/j.jvsv.2013.09.006. Epub 2014 Jan 16.

PMID:
26993177
23.

Prevalence of thrombophilia according to age at the first manifestation of venous thromboembolism: results from the MAISTHRO registry.

Weingarz L, Schwonberg J, Schindewolf M, Hecking C, Wolf Z, Erbe M, Weber A, Lindhoff-Last E, Linnemann B.

Br J Haematol. 2013 Dec;163(5):655-65. doi: 10.1111/bjh.12575. Epub 2013 Oct 8.

PMID:
24219332
24.

Patients with inferior vena cava thrombosis frequently present with lower back pain and bilateral lower-extremity deep vein thrombosis.

Kraft C, Hecking C, Schwonberg J, Schindewolf M, Lindhoff-Last E, Linnemann B.

Vasa. 2013 Jul;42(4):275-83. doi: 10.1024/0301-1526/a000288.

PMID:
23823859
25.

High incidence of heparin-induced allergic delayed-type hypersensitivity reactions in pregnancy.

Schindewolf M, Gobst C, Kroll H, Recke A, Louwen F, Wolter M, Kaufmann R, Boehncke WH, Lindhoff-Last E, Ludwig RJ.

J Allergy Clin Immunol. 2013 Jul;132(1):131-9. doi: 10.1016/j.jaci.2013.02.047. Epub 2013 May 30.

PMID:
23726261
26.

Heparin-induced skin lesions.

Schindewolf M, Lindhoff-Last E, Ludwig RJ, Boehncke WH.

Lancet. 2012 Nov 24;380(9856):1867-79. doi: 10.1016/S0140-6736(12)60409-7. Epub 2012 May 28. Review.

PMID:
22642893
27.

Performance of five D-dimer assays for the exclusion of symptomatic distal leg vein thrombosis.

Luxembourg B, Schwonberg J, Hecking C, Schindewolf M, Zgouras D, Lehmeyer S, Lindhoff-Last E.

Thromb Haemost. 2012 Feb;107(2):369-78. doi: 10.1160/TH11-07-0511. Epub 2012 Jan 11.

PMID:
22234425
28.

Application, tolerance and safety of fondaparinux therapy in a German hospital: a prospective single-centre experience.

Schindewolf M, Scheuermann J, Kroll H, Marzi I, Kaufmann R, Boehncke WH, Ludwig RJ, Lindhoff-Last E.

Thromb Res. 2012 Jan;129(1):17-21. doi: 10.1016/j.thromres.2011.06.008. Epub 2011 Jul 7.

PMID:
21741076
29.

Low allergenic potential with fondaparinux: results of a prospective investigation.

Schindewolf M, Scheuermann J, Kroll H, Garbaraviciene J, Hecking C, Marzi I, Wolter M, Kaufmann R, Boehncke WH, Lindhoff-Last E, Ludwig RJ.

Mayo Clin Proc. 2010 Oct;85(10):913-9. doi: 10.4065/mcp.2010.0346. Epub 2010 Sep 15.

30.

Heparin-induced non-necrotizing skin lesions: rarely associated with heparin-induced thrombocytopenia.

Schindewolf M, Kroll H, Ackermann H, Garbaraviciene J, Kaufmann R, Boehncke WH, Ludwig RJ, Lindhoff-Last E.

J Thromb Haemost. 2010 Jul;8(7):1486-91. doi: 10.1111/j.1538-7836.2010.03795.x. Epub 2010 Feb 1.

31.

Incidence and causes of heparin-induced skin lesions.

Schindewolf M, Schwaner S, Wolter M, Kroll H, Recke A, Kaufmann R, Boehncke WH, Lindhoff-Last E, Ludwig RJ.

CMAJ. 2009 Oct 13;181(8):477-81. doi: 10.1503/cmaj.081729. Epub 2009 Sep 28.

32.

Hereditary and acquired thrombophilia in patients with upper extremity deep-vein thrombosis. Results from the MAISTHRO registry.

Linnemann B, Meister F, Schwonberg J, Schindewolf M, Zgouras D, Lindhoff-Last E; MAISTHRO registry.

Thromb Haemost. 2008 Sep;100(3):440-6.

PMID:
18766260
33.

Fondaparinux-related thrombocytopenia in a patient with former HIT. Response to Rota et al. (Thromb Haemost 2008; 99: 779-781).

Schindewolf M, Lindhoff-Last E.

Thromb Haemost. 2008 Jul;100(1):168-9; author reply 169-70. doi: 10.1160/TH08-04-0222. No abstract available.

PMID:
18612559
35.

Etiology and VTE risk factor distribution in patients with inferior vena cava thrombosis.

Linnemann B, Schmidt H, Schindewolf M, Erbe M, Zgouras D, Grossmann R, Schambeck C, Lindhoff-Last E.

Thromb Res. 2008;123(1):72-8. doi: 10.1016/j.thromres.2008.01.004. Epub 2008 Mar 4.

PMID:
18295303
36.

Impact of sex and traditional cardiovascular risk factors on the risk of recurrent venous thromboembolism: results from the German MAISTHRO Registry.

Linnemann B, Zgouras D, Schindewolf M, Schwonberg J, Jarosch-Preusche M, Lindhoff-Last E.

Blood Coagul Fibrinolysis. 2008 Mar;19(2):159-65. doi: 10.1097/MBC.0b013e3282f54558.

PMID:
18277138
37.

Tolerance of fondaparinux in patients with generalized contact dermatitis to heparin.

Schindewolf M, Ludwig RJ, Wolter M, Himsel A, Zgouras D, Kaufmann R, Boehncke WH, Lindhoff-Last E.

J Eur Acad Dermatol Venereol. 2008 Mar;22(3):378-80. doi: 10.1111/j.1468-3083.2007.02333.x. No abstract available.

PMID:
18269612
38.

The influence of heparin's molecular weight and the incidence of delayed type hypersensitivity reactions revisited; in response to Grims et al., Br J Dermatol 2007; 157:514-17.

Ludwig RJ, Schindewolf M, Lindhoff-Last E, Boehncke WH.

Br J Dermatol. 2008 Apr;158(4):849-51. doi: 10.1111/j.1365-2133.2007.08402.x. Epub 2008 Jan 17. No abstract available.

PMID:
18205866
39.

Are patients with thrombophilia and previous venous thromboembolism at higher risk to arterial thrombosis?

Linnemann B, Schindewolf M, Zgouras D, Erbe M, Jarosch-Preusche M, Lindhoff-Last E.

Thromb Res. 2008;121(6):743-50. Epub 2007 Sep 4.

PMID:
17804043
40.

[Danaparoid in pregnancy in cases of heparin intolerance - use in 59 cases].

Schindewolf M, Magnani HN, Lindhoff-Last E.

Hamostaseologie. 2007 May;27(2):89-97. German.

PMID:
17479171
41.

Management of cutaneous type IV hypersensitivity reactions induced by heparin.

Ludwig RJ, Schindewolf M, Utikal J, Lindhoff-Last E, Boehncke WH.

Thromb Haemost. 2006 Nov;96(5):611-7. Review.

PMID:
17080218
42.

Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides.

Ludwig RJ, Schindewolf M, Alban S, Kaufmann R, Lindhoff-Last E, Boehncke WH.

Thromb Haemost. 2005 Dec;94(6):1265-9.

PMID:
16411404
43.

Influence of blood collection techniques on platelet function.

Mani H, Kirchmayr K, Kläffling C, Schindewolf M, Luxembourg B, Linnemann B, Lindhoff-Last E.

Platelets. 2004 Aug;15(5):315-8.

PMID:
15370102
44.

Safe anticoagulation with danaparoid in pregnancy and lactation.

Schindewolf M, Mosch G, Bauersachs RM, Lindhoff-Last E.

Thromb Haemost. 2004 Jul;92(1):211. No abstract available.

PMID:
15213864
45.

Heavy naphthen oil exhibits antipsoriatic efficacy in vivo and antiproliferative as well as differentiation-inducing effects on keratinocytes in vitro.

Thaci D, Schindewolf M, Smeh-Skrbin A, Krnjevic-Pezic G, Vrzogic P, Dobric I, Kaufmann R, Boehncke WH.

Arch Dermatol. 2000 May;136(5):678-9. No abstract available.

PMID:
10815873

Supplemental Content

Loading ...
Support Center